Session

IBD: Clinical trials poster I

LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN'S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY
LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN'S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY

GENE EXPRESSION PROFILING IN ULCERATIVE COLITIS IDENTIFIES CHARACTERISTICS FOR ANTI-TNF RESPONSE AND TARGETS FOR ALTERNATIVE THERAPIES
GENE EXPRESSION PROFILING IN ULCERATIVE COLITIS IDENTIFIES CHARACTERISTICS FOR ANTI-TNF RESPONSE AND TARGETS FOR ALTERNATIVE THERAPIES

MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS
MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS

PATIENTS WITH CROHN'S DISEASE HAVE IMPROVED COPING STRATEGIES AFTER A 3-MONTH COURSE OF COGNITIVE BEHAVIORAL AND MINDFULNESS-BASED STRESS REDUCTION
PATIENTS WITH CROHN'S DISEASE HAVE IMPROVED COPING STRATEGIES AFTER A 3-MONTH COURSE OF COGNITIVE BEHAVIORAL AND MINDFULNESS-BASED STRESS REDUCTION

EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY
AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY

PATIENTS WITH CROHN'S DISEASE HAVE IMPROVED COPING STRATEGIES AFTER A 3-MONTH COURSE OF COGNITIVE BEHAVIORAL AND MINDFULNESS-BASED STRESS REDUCTION
PATIENTS WITH CROHN'S DISEASE HAVE IMPROVED COPING STRATEGIES AFTER A 3-MONTH COURSE OF COGNITIVE BEHAVIORAL AND MINDFULNESS-BASED STRESS REDUCTION

IBD: Clinical trials poster I

EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

IBD: Clinical trials poster I

GENE EXPRESSION PROFILING IN ULCERATIVE COLITIS IDENTIFIES CHARACTERISTICS FOR ANTI-TNF RESPONSE AND TARGETS FOR ALTERNATIVE THERAPIES
GENE EXPRESSION PROFILING IN ULCERATIVE COLITIS IDENTIFIES CHARACTERISTICS FOR ANTI-TNF RESPONSE AND TARGETS FOR ALTERNATIVE THERAPIES

IBD: Clinical trials poster I

MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS
MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS

IBD: Clinical trials poster I

LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY
LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY

IBD: Clinical trials poster I

AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY
AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY

IBD: Clinical trials poster I  et al.

EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

IBD: Clinical trials poster I  et al.

PATIENTS WITH CROHN'S DISEASE HAVE IMPROVED COPING STRATEGIES AFTER A 3-MONTH COURSE OF COGNITIVE BEHAVIORAL AND MINDFULNESS-BASED STRESS REDUCTION
PATIENTS WITH CROHN'S DISEASE HAVE IMPROVED COPING STRATEGIES AFTER A 3-MONTH COURSE OF COGNITIVE BEHAVIORAL AND MINDFULNESS-BASED STRESS REDUCTION

IBD: Clinical trials poster I  et al.

MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS
MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS

IBD: Clinical trials poster I  et al.

GENE EXPRESSION PROFILING IN ULCERATIVE COLITIS IDENTIFIES CHARACTERISTICS FOR ANTI-TNF RESPONSE AND TARGETS FOR ALTERNATIVE THERAPIES
GENE EXPRESSION PROFILING IN ULCERATIVE COLITIS IDENTIFIES CHARACTERISTICS FOR ANTI-TNF RESPONSE AND TARGETS FOR ALTERNATIVE THERAPIES

IBD: Clinical trials poster I  et al.

LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY
LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY

IBD: Clinical trials poster I  et al.

Item 1 - 17 / 17
1